Investigational Site Number :7240002

Barcelona, Barcelona [Barcelona] 08035

1 studies enrolling now · 10 studies all time

What they study most

Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Obstructive Pulmonary Disease, Colorectal Cancer, Cutaneous Lupus Erythematosus, Gastric Cancer, Hepatocellular Carcinoma, Immune System Disorder, Malignant Solid Tumor, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Parkinson's Disease, Plasma Cell Myeloma Refractory

Studies at this site

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma — Recruiting now
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Completed
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis — Completed
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) — Completed
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation — Stopped early
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus — Completed
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation — Completed
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation — Completed
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation — Stopped early